Drugs / NAPROXEN ETEMESIL
NAPROXEN ETEMESIL
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00750243 | Sep 2008 → Feb 2009 | — | Logical Therapeutics | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01063920 | Feb → Nov 2010 | osteoarthritis | Logical Therapeutics | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NAPROXEN ETEMESIL | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105683 ↗ |
| Known as | LT-NS001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01063920 ↗ |
| Known as | MX-1094 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105683 ↗ |
| Modality | Small molecule | — CHEMBL2105683 ↗ |
| Route | Oral | “1200 mg b.i.d. p.o. for 12 weeks” NCT01063920 ↗ |